Regenxbio Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+7.43%
vs ±18.2% implied · ×0.41
shaded = implied · ▲▼ = realized
Regenxbio has 6 disclosed suppliers and 11 disclosed customers in SEC filings.
Regenxbio Inc.
7.20
SentenceIn March 2009, we entered into a license agreement with GSK, which was amended in April 2009, in order to secure the exclusive rights to patents and patent applications covering NAV Technology that GSK had previously licensed from Penn (subject to certain rights retained by GSK and Penn).
SentenceClearside will be responsible for supplying the SCS Microinjector in support of our preclinical studies, clinical studies and commercial use.
RGNX 10-Kaccession 0000950170-25-038770
SentenceIn August 2018, we entered into a license agreement with Emory University (Emory) for the exclusive rights to Emory's undivided interest in intellectual property that we and Emory jointly own relating to the delivery of AAV vectors to the CNS.
RGNX 10-Kaccession 0001193125-26-094013
SentenceIn June 2022, we entered into a license agreement with Johns Hopkins University (JHU) for the exclusive rights to JHU's undivided interest in intellectual property jointly owned by JHU and us relating to suprachoroidal delivery of anti-VEGF vectors.
RGNX 10-Kaccession 0000950170-25-038770
SentenceIn November 2014, we entered into a license agreement with Regents of the University of Minnesota (Minnesota) for the exclusive rights to Minnesota's undivided interest in intellectual property that Minnesota and we jointly own relating to the delivery of AAV vectors to the CNS.
RGNX 10-Kaccession 0001193125-26-094013
SentenceIn February 2009, we entered into an exclusive, worldwide license agreement with Penn for patent and other intellectual property rights relating to a gene therapy technology platform based on AAVs discovered at Penn in the laboratory of James M. Wilson, M.D., Ph.D.
RGNX 10-Kaccession 0001193125-26-094013
SentenceRoyalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are marketed by Novartis Gene Therapies, Inc. (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the treatment of spinal muscular atrophy (SMA).
SentenceThe Company has a license agreement with REGENXBIO, Inc., or REGENX, for an exclusive, sublicensable, worldwide commercial license under certain intellectual property for preclinical and clinical research and development, and commercialization of drug therapies using REGENX's licensed patents for the treatment of OTC deficiency and GSD1a.
SentenceWe recognized credit recoveries of $5.0 million during the year ended December 31, 2024 related to the full collection of amounts due under our settlement agreement with Abeona Therapeutics Inc. (Abeona), for which we had previously recorded an allowance for credit losses.
RGNX 10-Kaccession 0000950170-25-038770
SentenceWe have also taken an active role in the formation of several of our NAV Technology Licensees, including being a founding shareholder in Dimension Therapeutics, Inc., Prevail Therapeutics Inc. and Corlieve Therapeutics SAS, all of which were acquired in strategic transactions since their formation.
RGNX 10-Kaccession 0000950170-25-038770
SentenceWe have also taken an active role in the formation of several of our NAV Technology Licensees, including being a founding shareholder in Dimension Therapeutics, Inc., Prevail Therapeutics Inc. and Corlieve Therapeutics SAS, all of which were acquired in strategic transactions since their formation.
RGNX 10-Kaccession 0000950170-25-038770
SentenceInterest expense consists primarily of interest imputed on the liability related to the sale of future Zolgensma royalties to entities managed by Healthcare Royalty Management, LLC (collectively, HCR).
RGNX 10-Kaccession 0000950170-25-038770
SentenceIn December 2020, we sold a portion of our royalty rights from the net sales of Zolgensma to entities managed by Healthcare Royalty Management, LLC (HCR) for a gross purchase price of $200 million.
RGNX 10-Kaccession 0000950170-25-038770
SentenceUnder the terms of the Nippon Shinyaku Collaboration and License Agreement, we will receive an upfront payment of $110 million.
RGNX 10-Kaccession 0000950170-25-038770
SentenceWe have also taken an active role in the formation of several of our NAV Technology Licensees, including being a founding shareholder in Dimension Therapeutics, Inc., Prevail Therapeutics Inc. and Corlieve Therapeutics SAS, all of which were acquired in strategic transactions since their formation.
RGNX 10-Kaccession 0000950170-25-038770
Linked news
Expected move
Inputsspot 7.20exp Nov 20ATM strike 7ATM straddle 5.40IV 414%